Lyell Immunopharma (LYEL) Long-Term Investments (2020 - 2026)

Lyell Immunopharma's Long-Term Investments history runs 7 years deep, the most recent figure standing at $19.0 million for Q1 2026.

• In Q1 2026, Long-Term Investments fell 34.37% year-over-year to $19.0 million; the TTM figure through Mar 2026 stood at $19.0 million (down 34.37% YoY), while the FY2025 annual figure was $19.0 million, up 46.0% from the prior year.
• Long-Term Investments came in at $19.0 million for Q1 2026 at Lyell Immunopharma, roughly flat from $19.0 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $224.1 million in Q1 2022 to a low of $10.0 million in Q1 2023.
• A 5-year average of $46.5 million and a median of $20.1 million in 2024 frame the typical range for Long-Term Investments.
• Across the five-year window, Long-Term Investments plunged 95.54% in 2023 and surged 90.0% in 2024, its largest moves.
• Lyell Immunopharma's Long-Term Investments stood at $70.1 million in 2022, then sank by 76.46% to $16.5 million in 2023, then fell by 21.16% to $13.0 million in 2024, then surged by 46.0% to $19.0 million in 2025, then changed by 0.0% to $19.0 million in 2026.
• According to Business Quant data, Long-Term Investments over the past three periods registered $19.0 million, $19.0 million, and $20.1 million for Q1 2026, Q4 2025, and Q2 2025 respectively.

Peer Comparison